Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinitis Pigmentosa Clear all
Not listed Phase 1Phase 2 Interventional

Safety and Tolerability of hRPC in Retinitis Pigmentosa

NCT02464436
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
hRPC
Drug
Lead sponsor
ReNeuron Limited
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure (dose cohort 1&2 only)
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

NCT00661479
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, 100 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Jul 21, 2026, 4:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

NCT06646289
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AAV5-hRKp.RPGR, No intervention (Follow-Up assessment)
Biological · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
5 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational

Repository for Inherited Eye Diseases

NCT00378742
View directory record Official record
Conditions
Retinitis Pigmentosa, Inherited Ophthalmic Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
6,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Perceptual Experience of Argus II Users

NCT05285618
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Argus II
Device
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Santa Barbara, California • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

NCT05179460
View directory record Official record
Conditions
Pigmentary Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jul 21, 2026, 4:53 AM EDT
Recruiting Phase 1 Interventional

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

NCT06319872
View directory record Official record
Conditions
Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
Interventions
Oral disulfiram
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 21, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

NCT00078091
View directory record Official record
Conditions
Bardet-Biedl Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Argus II/ORCAM Device Study

NCT03248388
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Argus II Eyeglasses, ORCAM
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Jul 21, 2026, 4:53 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome

NCT00004345
View directory record Official record
Conditions
Usher Syndrome, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

NCT03322930
View directory record Official record
Conditions
Retinitis Pigmentosa, AMD
Interventions
Rod sensitivity
Diagnostic Test
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
10 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 21, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Clinical Registry Investigating Bardet-Biedl Syndrome

NCT02329210
View directory record Official record
Conditions
Bardet-Biedl Syndrome
Interventions
Not listed
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Exercise and RP (AVAMC and Emory)

NCT03381235
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Spin exercise
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

NCT01521793
View directory record Official record
Conditions
LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Interventions
QLT091001
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Jul 21, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

NCT06912633
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
human retinal progenitor cells, Mock injection
Biological · Other
Lead sponsor
jCyte, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Active, not recruiting Phase 3 Interventional

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

NCT04794101
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Genetic: AAV5-hRKp.RPGR Intermediate Dose, Genetic: AAV5-hRKp.RPGR Low Dose
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

NCT06891885
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

NCT06460844
View directory record Official record
Conditions
Retinitis Pigmentosa, Choroideremia
Interventions
RTx-015
Genetic
Lead sponsor
Ray Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Beverly Hills, California • Orange, California • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Argus® II Retinal Stimulation System Feasibility Protocol

NCT00407602
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Implant of Argus II Retinal Prosthesis
Device
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 21, 2026, 4:53 AM EDT
Withdrawn Not applicable Interventional

RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

NCT03629899
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
RETINA IMPLANT Alpha AMS
Device
Lead sponsor
Wills Eye
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jul 21, 2026, 4:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
View directory record Official record
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 4:53 AM EDT
Completed No phase listed Observational

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

NCT03314207
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Jul 21, 2026, 4:53 AM EDT